A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus

Human Gene Therapy

Volumn 12, Issue 9, 2001, Pages 1047-1061

  Xin, K Q ^a,b   Urabe, M ^b   Yang, J ^a   Nomiyama, K ^b   Mizukami, H ^b   Hamajima, K ^a   Nomiyama, H ^b   Saito, T ^a   Imai, M ^c   Monahan, J ^d   Okuda, K ^a,e   Ozawa, K ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c KANAGAWA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^d Avigen Inc   (United States)

^e TOKYO DENTAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN; REV PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; INFLUENZA VIRUS; MOUSE; NONHUMAN; VACCINATION; VIRUS STRAIN;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CYTOKINES; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; GENE PRODUCTS, REV; GENE PRODUCTS, TAT; GENES, ENV; GENES, TAT; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0034921072     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303401750214276     Document Type: Article

References (62)

1. In vivo model of adeno-associated virus vector persistence and rescue
2. Humoral and cell-mediated immune response to live recombinant BCG-HIV vaccines
3. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viremia
4. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
5. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration
6. Antibody responses raised against a conformational V3 loop peptide of HIV-1
7. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate
8. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
9. Venzuelan equine encephalitis virus vectors expressing HIV-1 proteins: Vector design strategies for improved vaccine efficacy
10. rAAV vectors as an AIDS vaccine
11. Selective uptake and sustained expression of AAV vectors following subcutaneous delivery
12. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector
13. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors
14. Recombinant adeno-associated virus for muscle directed gene therapy
15. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector
16. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine
17. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus ankara boost vaccination regimen
18. Toward an understanding of the correlates of protective immunity to HIV infection
19. Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells
20. + T lymphocytes producing tumor necrosis factor α spots in response to peptide antigens
21. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
22. Researchers and regulators reflect on first gene therapy death
23. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
24. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain
25. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
26. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line
27. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
28. Site-specific integration by adeno-associated virus
29. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
30. Human immunodeficiency virus (HIV) Nef-specific cytotoxic T lymphocytes in non-infected heterosexual contact of HIV-infected patients
31. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa
32. Immunodeficiency virus Rev trans-activator modulates the expression of the viral regulatory genes
33. in vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model
34. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D
35. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
36. Induction of protective immunity against pathogenic simian immunodeficiency virus by a foreign receptor-dependent replication of an engineered avirulent virus
37. AIDS pathogenesis: A finite immune response to blame?
38. Quantification of antigen specific CD8+ T cells using an ELISPOT assay
39. Live-attenuated HIV vaccines: How safe is safe enough?
40. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV-1 env and rev gene products
41. Vaccination with Rev and Tat against AIDS
42. + T cells with a predominant Vβ usage during the primary immune response to HIV
43. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors
44. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques
45. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts
46. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
47. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
48. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors
49. Recombinant rabies virus as potential live-viral vaccines for HIV-1
50. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
51. Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: Comparison with adenovirus vectors
52. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS
53. Perfluorochemical liquid enhances adeno-associated virus-mediated transgene expression in lungs
54. Adaptation to persistent growth in the H9 cell renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera
55. Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus
56. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector
57. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenoivurs
58. Intranasal administration of HIV-1 DNA vaccine with IL-2 expression plasmid enhances cell-mediated immunity against HIV-1
59. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine
60. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity
61. Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols
62. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS